Table 1.
Impact of Preoperative Chemotherapy for Colorectal Liver Metastases on Surgical Outcome Following Liver Resection
| Series | Number of Patients | FU-Based Chemotherapy | Oxaliplatin-Based Chemotherapy | Irinotecan-Based chemotherapy | Mean Number of Cycles | Interval between Chemotherapy and Liver Resection (wk) | Major (≥ 3 Liver Segments) /Minor Liver Resection | Impact of Chemotherapy on Postoperative Morbidity | Impact of Chemotherapy on Postoperative Mortality |
|---|---|---|---|---|---|---|---|---|---|
| FU, fluorouracil; NA, not applicable. | |||||||||
| Parc et al21 | 17 | 17 (100%) | 0 | 0 | NA | < 12 | 17 | No | No |
| Yedibela et al22 | 32 | NA | NA | NA | NA | NA | 9–23 | No | No |
| Karoui et al17 | 45* | 12 (25%) | 38 (84.4%) | 14 (31.1%) | 6 | < 8 | 45 | Yes | No |
| Vauthey et al18 | 248 | 63 (25.4%) | 79 (31.8%) | 94 (37.9%) | 8 (16 wk) | 6.4 | 163/85 | No | Yes† |
| Aloia et al23 | 75 | 52 (69%) | 23 (31%) | 0 | > 6 for 46 patients | < 24 | 43/32 | No | No |
| Sahajpal et al24 | 53 | 35 (66%) | 9 (17%) | 0 | 5.7 | 12 | 43; ≥ 2 liver segments | No | No |
| Hewes et al25 | 46 | 25 (54%) | 21 (46%) | 1 (2%) | 6 | < 60 | NA | No | No |
| Pawlik et al26 | 153 | 67 (44%) | 55 (36%) | 31 (20.2%) | < 6 for 99 patients | NA | 64/89 | No | No |
*
Some patients received more than one line of chemotherapy regimen.
†
Irinotecan-based chemotherapy was associated with chemotherapy-associated steatohepatitis (CASH); CASH was associated with increased 90 days postoperative mortality.